Clinical trial
Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria
NCT00130000 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00130000 |
|---|---|
| Title | Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria |
| Official title | SHEPHERD: Safety in Hemolytic PNH Patients Treated With Eculizumab: A Multi-Center Open-Label Research Design |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Paroxysmal Hemoglobinuria, Nocturnal |
| Intervention type | Drug |
| Interventions | Eculizumab |
| Enrollment | 87 |
| Start date | Aug 9, 2005 |
| Completion | Jun 25, 2007 |
| First posted | Aug 12, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: